ketorolac has been researched along with Facial Pain in 9 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The decrease in postoperative pain was measured as the primary outcome variable." | 2.78 | Does ketorolac have a preemptive analgesic effect? A randomized, double-blind, control study. ( Gutta, R; James, LE; Koehn, CR, 2013) |
| " Pain levels were also recorded at 15 and 30 minutes after the initial IN dosing (before endodontic treatment); 30 minutes after completion of endodontic treatment; and 4, 8, and 12 hours after the initial IN spray." | 2.76 | Sniffing out endodontic pain: use of an intranasal analgesic in a randomized clinical trial. ( Bowles, WR; Eggleston, GW; Johnson, N; Lunos, S; Turner, CL; Wiedmann, TS, 2011) |
| "Parecoxib 20 mg i." | 2.71 | The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain. ( Daniels, S; Desjardins, PJ; Hubbard, RC; Mehlisch, DR, 2004) |
| " The selective COX-2 inhibitors hold promise for clinical efficacy with less toxicity from chronic administration and may prove advantageous for the relief of chronic orofacial pain." | 2.41 | Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry. ( Berthold, CW; Dionne, RA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gutta, R | 1 |
| Koehn, CR | 1 |
| James, LE | 1 |
| Barreras-Espinoza, I | 1 |
| Soto-Zambrano, JA | 1 |
| Serafín-Higuera, N | 1 |
| Zapata-Morales, R | 1 |
| Alonso-Castro, Á | 1 |
| Bologna-Molina, R | 1 |
| Granados-Soto, V | 1 |
| Isiordia-Espinoza, MA | 1 |
| Bendixen, KH | 1 |
| Baad-Hansen, L | 1 |
| Cairns, BE | 1 |
| Svensson, P | 1 |
| Turner, CL | 1 |
| Eggleston, GW | 1 |
| Lunos, S | 1 |
| Johnson, N | 1 |
| Wiedmann, TS | 1 |
| Bowles, WR | 1 |
| Dong, L | 1 |
| Guarino, BB | 1 |
| Jordan-Sciutto, KL | 1 |
| Winkelstein, BA | 1 |
| Mehlisch, DR | 1 |
| Desjardins, PJ | 1 |
| Daniels, S | 1 |
| Hubbard, RC | 1 |
| Hargreaves, KM | 1 |
| Dionne, RA | 1 |
| Berthold, CW | 1 |
| Saxen, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preliminary Studies for Whole Genome Association Study (WGAS) in Acute Perioperative Pain[NCT01557751] | 156 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint is the pain reported by subjects, using the NRS-Pain with movement on the second day after surgery.The assumption behind this study is that certain genetic variants (e.g. single-nucleotide polymorphism (SNP) are responsible for part of total variation of certain clinical phenotypes (e.g. post-operative pain here).~Numeric Rating Score Pain Assessment (0-10 scale where 0 indicates no pain at all and 10 indicates the worst pain imaginable) on Post Op Day 2, Pain with Movement" (NCT01557751)
Timeframe: Postoperative day (POD) 2
| Intervention | units on a scale (Mean) |
|---|---|
| Total Knee Arthroplasty Subjects Who Are Genotyped | 2.83 |
2 reviews available for ketorolac and Facial Pain
| Article | Year |
|---|---|
Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; beta-Endorphin; Cyclooxygenase 2; Cyclo | 2001 |
The clinical pharmacology of Ketorolac.
Topics: Analgesics; Anesthesia, Dental; Anti-Inflammatory Agents, Non-Steroidal; Facial Pain; Humans; Inject | 1992 |
4 trials available for ketorolac and Facial Pain
| Article | Year |
|---|---|
Does ketorolac have a preemptive analgesic effect? A randomized, double-blind, control study.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Doubl | 2013 |
Effects of low-dose intramuscular ketorolac on experimental pain in the masseter muscle of healthy women.
Topics: Adult; Analysis of Variance; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Area Under | 2010 |
Sniffing out endodontic pain: use of an intranasal analgesic in a randomized clinical trial.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chroni | 2011 |
The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase 2; Cyclooxygenase | 2004 |
3 other studies available for ketorolac and Facial Pain
| Article | Year |
|---|---|
The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Facial Pain; | 2017 |
Activating transcription factor 4, a mediator of the integrated stress response, is increased in the dorsal root ganglia following painful facet joint distraction.
Topics: Activating Transcription Factor 4; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Re: The use of an intra-oral injection of ketorolac in the treatment of irreversible pulpitis.
Topics: Administration, Buccal; Anti-Inflammatory Agents, Non-Steroidal; Facial Pain; Humans; Injections; Ke | 2006 |